Attendee search 

Celumigen Pharmaceuticals is a California- headquartered seed stage specialty pharmaceutical company in dermatology focused on developing the first FDA-approved topical prescription immunotherapeutic drug for Cutaneous viral warts; a widespread global disease affecting greater than 500MM people in China, and 78% of the world's population. The global markets have seen no approved prescription therapies for HPV, Common warts and no therapies that eradicate this disease on the market or in the pipeline-- we plan to capture and grow this lucrative market. Our therapeutic is a likely 505 (b) 2 FDA designated drug. Our leadership, development and clinical team is a group of world class leaders with deep industry knowledge and unparalleled domain expertise. We have raised a seed round led by industry- leading investors which funded a Proof of Concept study with very positive confirmatory results and data to support our Phases I and Phase II. We are now seeking strategic partnership with a company seeking to support drug development to enhance existing dermatology drug asset portfolios or fund our program through venture capital / partnership.

VITANLINK is a holding structure for business creation and project acceleration in deep tech fields such as AI, ICT and IoT applied to various sectors such as healthcare, finance, media and retail.
Within a competitive timeframe, start-ups and small and medium-sized businesses successfully move from seed to post-seed stages, from growth to scaling up to new markets
In partnership with family offices, advisory boutiques, regional accelerators and investment funds

My office provides low cost funding for business expansion or new market placements. We also offer high level official European framework for risk management and project mediation for large greenfield projects as to comply to the standards and principles of Development funds , thereby giving you a way for mid size entrepreneurs to be funded either partial or in full by large Development Funds.

Alternative protein with microalgae

A startup biotech focusing on novel therapeutic antibody discovery and development, particularly in fully human nanobody and bispecifics. Recently closed a Series A fund raising (USD $25M ).

苏州博奥明赛生物制药有限公司是一家专注于创新生物大分子药的研发型公司。公司已经建立起了多个国际领先的全人源快速抗体发现与优化平台，其中包括国际领先的全人源纳米抗体和双特异性抗体平台以及国际上库容量最大的噬菌体，酵母菌，和哺乳动物细胞展示平台。公司依托平台优势，在较短的时间内已经拥有十多个在研全新生物大分子药物，包括多个国际上首创的全人源纳米抗体（VH）和双特异性抗体。本轮融资资金将主要用于推进其中两个先导项目的临床前开发。